SOM Biotech licenses its first product and expands to the United States

The med-tech biopharmaceutical company SOM Biotech, specializing in repurposing drugs to treat rare nervous system diseases, has concluded a worldwide license agreement with Corino Therapeutics Inc. to clinically develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement had been reached, the drug achieved very promising results in a Phase 2 study conducted in Europe.

The geographic expansion, and the clinical development of SOM’s most advanced assets, will be capitalized through the licensing revenues from SOM0226, as well as the commencing Series A fundraising, targeted to leading US and European venture investors.

Press Release English

Press Release Spanish

Press Release Catalan